Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy by Cao, Maria D et al.
RESEARCH ARTICLE Open Access
Prognostic value of metabolic response in breast
cancer patients receiving neoadjuvant
chemotherapy
Maria D Cao
1,8*†, Guro F Giskeødegård
1†, Tone F Bathen
1,2, Beathe Sitter
1,2, Anna Bofin
3, Per E Lønning
4,5,
Steinar Lundgren
1,6,7 and Ingrid S Gribbestad
1
Abstract
Background: Today’s clinical diagnostic tools are insufficient for giving accurate prognosis to breast cancer
patients. The aim of our study was to examine the tumor metabolic changes in patients with locally advanced
breast cancer caused by neoadjuvant chemotherapy (NAC), relating these changes to clinical treatment response
and long-term survival.
Methods: Patients (n = 89) participating in a randomized open-label multicenter study were allocated to receive
either NAC as epirubicin or paclitaxel monotherapy. Biopsies were excised pre- and post-treatment, and analyzed
by high resolution magic angle spinning magnetic resonance spectroscopy (HR MAS MRS). The metabolite profiles
were examined by paired and unpaired multivariate methods and findings of important metabolites were
confirmed by spectral integration of the metabolite peaks.
Results: All patients had a significant metabolic response to NAC, and pre- and post-treatment spectra could be
discriminated with 87.9%/68.9% classification accuracy by paired/unpaired partial least squares discriminant analysis
(PLS-DA) (p < 0.001). Similar metabolic responses were observed for the two chemotherapeutic agents. The
metabolic responses were related to patient outcome. Non-survivors (< 5 years) had increased tumor levels of
lactate (p = 0.004) after treatment, while survivors (≥ 5 years) experienced a decrease in the levels of glycine (p =
0.047) and choline-containing compounds (p ≤ 0.013) and an increase in glucose (p = 0.002) levels. The metabolic
responses were not related to clinical treatment response.
Conclusions: The differences in tumor metabolic response to NAC were associated with breast cancer survival, but
not to clinical response. Monitoring metabolic responses to NAC by HR MAS MRS may provide information about
tumor biology related to individual prognosis.
Background
The prognosis of patients with locally advanced breast
cancer varies largely due to the heterogeneity of the dis-
ease, and 5-year survival rates from 50 to 80% have
been reported [1]. Neoadjuvant chemotherapy (NAC)
has been established as a standard treatment for locally
advanced breast cancer, with anthracyclines and taxanes
being among the most frequently used agents. NAC is
provided to make primarily inoperable tumors
resectable, and will also increase the rate of breast-con-
serving surgery without any significant increase in local
or distal recurrence [2,3]. Studies investigating the meta-
bolic responses and chemoresistance to single or a com-
bination of drugs are important for effective treatment
and better patient outcome.
Patients with a pathological complete response (pCR)
after NAC have improved outcome compared to
patients with residual disease, thus treatment response
i sap r o g n o s t i ci n d i c a t o r .H o w e v e r ,o n l y~ 2 0 %o f
patients will achieve a pCR to NAC [4]. Other prognos-
tic factors of breast cancer include axillary lymph node
status, tumor size, Her-2 overexpression,
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The status of Her-2 and hormone receptors is also pre-
dictive of treatment response. Identification of other
markers for prognosis and treatment response may help
stratify patients for better individualized treatment.
Several studies have shown altered metabolism in can-
cer compared to normal tissue. Elevated levels of total
choline-containing compounds (tCho) are frequently
observed in cancer, and may serve as magnetic reso-
nance spectroscopy (MRS) markers for malignancy, both
in vivo and ex vivo [5,6]. The tCho signal constitutes
signals from glycerophosphocholine (GPC), phospho-
choline (PC) and free choline (Cho) which are involved
in phospholipid metabolism through the Kennedy path-
way. A decreased level of tCho detected by in vivo MRS
has been suggested as a possible marker for treatment
response [7,8]. Altered concentrations of other tissue
metabolites, such as increased levels of lactate, have also
been associated with malignancy [9,10]. Elevated lactate
levels may be related to hypoxia, a common feature of
solid tumors where glucose is catabolised to lactate due
to the lack of oxygen. Also under conditions with suffi-
cient oxygen levels, cancer cells may convert glucose to
lactate, described as the Warburg effect.
High resolution magic angle spinning (HR MAS) MRS
is a non-destructive technique providing highly resolved
MR spectra of intact tissues with minimal sample pre-
paration. HR MAS MR spectra provide an overview of
the different metabolites that are present in a tissue
sample, and can give insight into the complex processes
leading to cancer and other diseases. More than 30
metabolites have been identified in breast tissue using
HR MAS MRS [11]. Systematic studies of the metabolic
state of biological systems using multivariate analysis
methods are referred to as metabolomics. MR metabolo-
mics studies of breast cancer have revealed correlations
between tissue metabolic profiles and clinical prognostic
factors such as hormone receptor status, grade and lym-
phatic spread [12-14]. Long-term survival of breast can-
cer patients has been successfully predicted from breast
cancer tissue using multivariate classification models
[15]. The purpose of this study was to examine the
metabolic changes in breast cancer tissues resulting
from treatment with NAC, and to relate these changes
to treatment response and long-term survival. This is
the first study to investigate the metabolic response of
NAC in a large breast cancer cohort using ex vivo MRS.
Methods
Patient and tumor characteristics
We examined a subcohort of breast cancer patients (n =
89) from a larger open-label multicenter study where
patients were randomly allocated to receive NAC treat-
ment with either anthracycline (epirubicin, 90 mg/m
2)
or taxane (paclitaxel, 200 mg/m
2) monotherapy [16].
The patients were given subsequent adjuvant endocrine
treatment according to guidelines from the Norwegian
Breast Cancer Group. The inclusion criteria and treat-
ment protocol are fully described elsewhere [16]. Briefly,
female breast cancer patients at pre/post menopausal
age (≤ 70 years) with locally advanced (stage III, T3/4
and/or N2) non-inflammatory breast cancer with or
without limited distant metastasis were recruited in the
period 1997-2003. The patients were treated every third
week for four cycles. Patients showing a non-satisfactory
response were assigned to the opposite treatment. From
each patient, an incisional biopsy was taken before treat-
ment with NAC and a post-treatment biopsy was
excised during surgical removal of the tumor. The biop-
sies were immediately snap-frozen and stored in -80°C
a n ds u b s e q u e n t l yi nl i q u i dn i t r o g e ni nab i o b a n ku n t i l
use. A part of the pre-treatment tumor biopsy was
obtained for routine pathological diagnosis and hormone
status assignment. Estrogen (ER) and progesterone
receptor (PgR) status were determined by immunohisto-
chemical staining (positive ≥ 10% staining cells). The
study was approved by The Regional Committee for
Medical and Health Research Ethics (Norwegian Health
Region III) and informed written consent was obtained
from all patients
Response and survival evaluation
Response to treatment was evaluated using the WHO
criteria by the UICC system [17]. Treatment response
was assessed clinically by comparing caliper measure-
ments prior to NAC treatment and after the last cycle.
In the subcohort included in this study, the patients
were classified to have either partial response (≥ 50%
reduction in tumor size (the product of the two largest
tumor diameters) after treatment, but not complete
response) or stable disease (< 50% reduction to ≤ 25%
increase in tumor size after treatment). Patients
deceased within 5 years after diagnosis were classified as
non-survivors whereas patients surviving 5 years or
more were classified as survivors.
Histopathological examinations
Prior to HR MAS MRS analysis, imprint cytology
smears were prepared from the tissue samples and
stained with the May-Grünwald-Giemsa stain (Color-
Rapid, Med-Kjemi, Norway). Confirmation of tumor cell
content was determined microscopically by a
cytopathologist.
HR MAS MRS experiments
HR MAS MRS analyses were performed on a Bruker
Avance DRX600 spectrometer (Bruker Biospin GmbH,
Germany) equipped with a
1H/
13 C MAS probe with
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days. Each sample (15.1 ± 2.8 mg) was cut to fit a 30 μl
leak-proof disposable insert (Bruker Biospin Corp, USA)
and added phosphate buffered saline (PBS, 3 μl) in D2O
containing trimethylsilyl tetradeuteropropionic acid
(TSP, 98.2 mM) for chemical shift referencing. Samples
were spun at 5 kHz and spectra were recorded within
31 min per sample at 4°C to minimize tissue degrada-
tion. Spin-echo spectra (cpmgpr; Bruker) were recorded
as previously described [14].
Data preprocessing
Twenty eight spectra were excluded from further studies
due to low tumor cell content. The resulting data set
consisted of 150 spectra from 85 patients (70 pre-treat-
ment and 80 post-treatment spectra). Characteristics of
the included patients and tumors are listed in Table 1.
The MR spectra were Fourier transformed into 128 K
after 0.3 Hz exponential line broadening. Chemical shifts
were referenced to the TSP peak at 0 ppm. The spectral
region between 4.69 and 1.45 ppm, excluding the water
peak and large lipid residuals, was chosen for analysis.
Signals from ethanol pollutions between 3.69 and 3.57
ppm were removed together with lipid residual signals
between 3.01 and 1.52 ppm. The spectra were baseline
corrected using asymmetric least squares [18] with
parameters l = 1e7 and p = 0.0001, and the minimum
value of each spectrum was set to zero by subtracting
the lowest value. The spectra were normalized to equal
total area, and peak aligned using icoshift [19].
Multivariate data analysis
Partial least squares (PLS) analysis is a regression
method for analysis of collinear data with numerous
variables. The method is based on extraction of underly-
ing structures, or latent variables (LVs), that maximize
the covariance between X (the spectra) and a response
variable Y [20]. PLS discriminant analysis (PLS-DA)
attempts to discriminate between distinct classes. PLS-
DA was performed in Matlab R2009a (The Mathworks,
Inc., USA) using PLS_Toolbox 6.2.1 (Eigenvector
Research, USA). A PLS-DA model was built on mean-
centred spectra from randomly chosen training samples
(90% of the patients) and used to predict the status of
test samples (the remaining 10%). This procedure was
repeated 20 times and the average classification results
were calculated. The number of LVs to use was chosen
by cross-validation of the whole data set and used for all
repetitions to avoid biased results. The importance of
each variable in the loadings of the PLS-DA was evalu-
ated by variable importance in the projection (VIP)
scores [21]. The VIP score positively reflects the vari-
able’s influence on the classification, and variables with
Table 1 Patient and tumor characteristics
Survivors Non-survivors NA*
(n = 60) (n = 23) (n = 2)
Mean age (± SD) years 51.1 ± 10.6 49.3 ± 8.3 46.4 ± 2.6
Mean tumor dimensions (mean ± SD) mm 67.9 × 67.9 ± 18.0 × 19.8 78.6 × 77.3 ± 22.0 × 24.0 65.0 × 51.5 ± 7.1 × 26.2
NAC treatment Epirubicin 25 8 -
Paclitaxel 23 5 2
Both
1 12 10 -
Treatment Partial response 40 11 1
response Stable disease 20 12 1
AJCC IIB 21 7 1
IIIA 25 11 1
IIIB 12 2 -
IV 2 3 -
ER status + 41 7 2
-1 9 1 5 -
unknown - 1 -
PgR status + 32 14 2
-2 8 1 8 -
unknown - 1 -
Nodes + 32 14 1
-2 8 9 1
Metastasis + 2 2 0
- 5 82 12
*NA, not applicable–One patient without following up and one patient dead by other causes; AJCC, American Joint Committee on Cancer; Both
1, sequential
treatment with Epirubicin and Paclitaxel
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tant [21,22]. To evaluate the statistical significance of
the classification results, permutation testing was per-
formed [23]. In permutation testing, the class labels are
permuted to resemble random classification. It is then
possible to examine if the achieved prediction results of
the original data set are significantly different than ran-
dom predictions. The data set with the permuted class
label was divided into training and test sets repeated 20
times as described for the original data set, and the
average results were calculated. The permutation proce-
dure was repeated 1,000 times, and the prediction error
of the original data set was compared to the distribution
of prediction errors from the permutation. P-values ≤
0.05 were considered significant.
Multilevel PLS-DA [24,25] is an extension of ordinary
PLS-DA which can be used as a paired analysis for mul-
tivariate data. This analysis can only be used when the
data has a multilevel structure, i.e. when interventions
are evaluated on the same subject. In multilevel PLS-
DA, the between subject variation is separated from the
within subject variation. This is useful in metabolic pro-
filing as the variation between subjects, resulting from
differences in age, disease state, genetics and other fac-
tors, can obscure the metabolic changes caused by the
intervention. The between subject variation is described
by the average of the two observations (pre- and post-
treatment) from each subject, whereas the within subject
variation is described by the net difference between the
two observations (pre- and post-treatment). Multilevel
PLS-DA was used to examine metabolic changes in the
spectra resulting from NAC treatment. The split-up of
variation was done using algorithms made available by
van Velzen et al. [24]. Further PLS-DA classifications of
the within subject variation were performed using
PLS_Toolbox as described for the unpaired analyses.
The net difference of the spectra pre- minus post-treat-
ment (positively representing the metabolites higher
expressed before treatment) is annotated as control,
while the net difference post- minus pre-treatment
(positively representing the metabolites higher expressed
after treatment) is annotated as treatment. More specifi-
cally,
control = A − B
treatment = B − A
(1)
where the matrix A represents pre-treatment spectra,
and matrix B represents the post-treatment spectra.
Univariate data analysis
To further validate the important metabolites from the
PLS-DA models, relative intensities were found by inte-
grating the peak areas of spectra normalized to equal
total areas after removal of lipid residuals (Matlab
R2009a, The Mathworks, Inc., USA). Normalization of
spectra with the lipid residual signals removed will cor-
rect for differences in sample size and tumor cell con-
tent, as it can be assumed that most of the lipid signals
from breast samples do not originate from cancer cells.
Group differences were statistically tested by Wilcoxon
rank sum tests or Wilcoxon sign rank for paired ana-
l y s e s ,a n dc o n s i d e r e ds i g n i f i c a n ti ft h ep - v a l u e sw e r e≤
0.05.
Results
Metabolic response to neoadjuvant chemotherapy
All classification results are summarized in Table 2. An
unpaired PLS-DA of the pre- and post-treatment spectra
of the whole data set showed a significant difference in
the metabolite profiles in response to NAC treatment,
indicating a metabolic response to NAC in all patients.
However, the specificity of the classification was low
(57.1%). When comparing the classification errors of
PLS-DA and paired multilevel PLS-DA from 20 different
test sets, the multilevel PLS-DA with split-up of the var-
iation decreased the classification error significantly
(Wilcoxon rank sum test, p < 0.001), showing the bene-
ficial effect of the paired analysis. Treatment and control
spectra could be separated with a sensitivity and specifi-
city of 87.9%. Figure 1A shows the scores and loadings
of the multilevel PLS-DA. Lactate and PC were of high
importance for the discrimination according to the VIP
scores in the loadings. The levels of lactate and glycine
appear to be increased in response to treatment, while
the levels of PC are markedly decreased for some
patients. In addition, GPC levels appear to be decreased
in response to treatment. No clustering according to the
given chemotherapeutic agents could be seen in the
multilevel PLS-DA score plot (results not shown), thus
the metabolic treatment effects of epirubicin and pacli-
taxel appear to be indistinguishable.
No differences in metabolic response between clinical
response groups
The patients were divided into two groups according to
their clinical response (partial response or stable dis-
ease), and multilevel PLS-DA was performed on each
group separately in order to discover potential differ-
ences in metabolic treatment response between the
groups. Both for patients with partial response and
stable disease there was a significant change in the
tumor metabolism in response to NAC treatment, and
treatment spectra could be discriminated from controls
with a sensitivity and specificity ≥ 80.0%. The metabolic
response to NAC as observed in the loading plots was
similar for both subgroups, resembling the changes
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Thus, no difference in the metabolic response could be
detected between patients with stable disease and partial
response.
Different metabolic responses correlate with survival
The patients were also divided into two groups accord-
ing to their survival status (5-year survivors or non-sur-
vivors). Both for survivors and non-survivors there was
a clear change in the tumor metabolism in response to
NAC treatment (Figure 1B and 1C), and treatment spec-
tra could be discriminated from controls with a sensitiv-
ity and specificity ≥ 82.5%. However, the metabolic
treatment response appears to differ between survivors
and non-survivors.
The loadings showed unchanged lactate levels in
response to treatment in survivors, while lactate
increased in non-survivors with high importance for the
discrimination according to the VIP scores. This was
confirmed by comparison of the relative intensities from
metabolite integrals, showing a significant increase in
lactate levels in response to treatment in non-survivors
(p = 0.004) but not in survivors (Table 3).
Glycine appears to be decreased in survivors according
to the loadings, and the difference in relative intensities
before and after treatment was significant (p = 0.047).
For non-survivors, the glycine level appears to be high
in some samples from both the control and the treat-
ment group; hence the role of glycine in the loading
plot is more difficult to interpret. The glycine change
from integrated relative intensities was not significant in
non-survivors, with a mean value close to zero.
GPC levels were decreased in the loading plot of sur-
vivors with VIP scores showing high importance, while
changes in GPC levels in non-survivors were less impor-
tant for the discrimination.A c c o r d i n g l y ,t h er e l a t i v e
intensities of GPC were significantly lower in response
to treatment in survivors (p <0 . 0 0 1 )b u tn o ti nn o n -
survivors.
The loadings show decreased levels of PC in response
to treatment in both survivors and non-survivors. How-
ever, the change in PC relative intensities was only sig-
nificant for survivors (p < 0.001), but not for non-
survivors, possibly due to a high standard error.
Relative intensities of Cho levels were significantly
decreased in survivors (p = 0.013) in response to treat-
ment, but only a trend of decreased Cho levels was seen
in non-survivors (p = 0.084). In addition, glucose was
significantly increased in survivors (p =0 . 0 0 2 ) .C h oa n d
g l u c o s ew e r en o tp r o t r u d i n gin the loadings, possibly
due to low intensity values.
As an overall measure of the partly overlapping cho-
line-containing metabolite peaks (GPC, PC, and Cho),
the changes in relative intensities of tCho were
Table 2 Classification results from multilevel PLS-DA and PLS-DA
Class. model No. of
LVs
Variance
X/Y
(%)
Sensitivity/
Specificity
(%)
Class.
accuracy
(%)
Permutation
p-value
Paired data All samples Control vs
Treatment
(n =
65p)
Multilevel PLS-
DA
2 58.9/50.9 87.9/87.9 87.9 < 0.001
Partial
response
Control vs
Treatment
(n =
37p)
Multilevel PLS-
DA
2 55.7/61.7 80.0/80.0 80.0 < 0.001
Stable disease Control vs
Treatment
(n =
28p)
Multilevel PLS-
DA
2 63.2/61.3 88.7/88.7 88.7 < 0.001
Survivors Control vs
Treatment
(n =
44p)
Multilevel PLS-
DA
2 60.0/50.5 83.0/83.0 83.0 < 0.001
Non-survivors Control vs
Treatment
(n =
19p)
Multilevel PLS-
DA
2 70.6/63.9 82.5/82.5 82.5 0.006
Unpaired
data
All samples Pre- vs
Post-treatment
(n =
65p)
PLD-DA 2 50.3/29.2 80.7/57.1 68.9 < 0.001
Pre-treatment Partial response vs
Stable disease
(n = 48)
(n = 32)
PLS-DA 2 51.5/19.3 56.7/60.2 58.4 0.231
Post-
treatment
Partial response vs
Stable disease
(n = 41)
(n = 29)
PLS-DA NaN - - - -
Pre-treatment Survivors vs
Non-survivors
(n = 57)
(n = 20)
PLS-DA NaN - - - -
Post-
treatment
Survivors vs
Non-survivors
(n = 47)
(n = 21)
PLS-DA 3 62.8/32.1 58.4/75.3 70.1 0.009
Post-
treatment
Epirubicin vs
Paclitaxel
(n = 29)
(n = 23)
PLS-DA 2 45.7/26.8 45.0/48.3 46.5 0.245
The sensitivity is for detecting a treatment/stable disease/non-survivor/Paclitaxel spectrum; Variance X/Y, amount of variance from X/Y explained by the model;
NaN, no valid model; p, pairs
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Page 5 of 11Figure 1 Scores and loadings from multilevel PLS-DA. The score and loading plots show the two first latent variables separating treatment
and control spectra based on (A) the whole data set, (B) 5-year survivors, and (C) non-survivors. The variables in the loadings are colored
according to VIP scores, indicating the importance of each variable in the discrimination. The control spectra equal the difference between pre-
and post-treatment spectra, while the treatment spectra equal the difference between post- and pre-treatment spectra. The most protruding
differences in the loading plots of (B) survivors and (C) non-survivors show a decrease in GPC levels in survivors after treatment, while non-
survivors have increased levels of lactate. PC appears to be present in high levels in some samples of both survivors and non-survivors. Lac,
lactate; Gly, glycine; b-Glc, b-glucose.
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levels in response to treatment (p <0 . 0 0 1 ) ,w h i l ea
trend of decreased tCho levels were detected in non-sur-
vivors (p = 0.091).
Metabolic traits at pre- and post-treatment
A PLS-DA of the post-treatment spectra showed a sig-
nificant difference in the metabolite profiles of 5-year
survivors and non-survivors after treatment with 70.1%
correct classification (Table 2). According to the scores
and loadings shown in Figure 2, the tumors of non-sur-
vivors appear to have more of the metabolites lactate
and glycine, and less GPC and taurine than survivors
post-treatment. PC appears to be present in high levels
in some samples of both survivors and non-survivors.
The glycine level was denoted to be of major impor-
tance according to the VIP scores, and the relative
intensities of glycine were significantly higher in non-
survivors compared to survivors post-treatment (p =
0.033, Table 4). Similarly, a trend of higher relative
intensities of lactate was observed in non-survivors (p =
0.089). No significant differences in the relative intensi-
ties of taurine and GPC were observed, however differ-
ences in the levels of tCho approached significance (p =
0.075) with non-survivors having higher relative intensi-
ties than survivors post-treatment.
The metabolic differences between survivor and non-
survivors were not seen pre-treatment as the multivari-
ate model could not discriminate the two outcome
groups (model not valid). Furthermore, none of the
metabolites showed significant differences in relative
intensities between survivors and non-survivors pre-
treatment (Table 4).
No significant differences in the metabolite profiles at
pre- or post-treatment were detected between patients
with partial responders and stable disease by PLS-DA.
Post-treatment spectra from patients treated with Epiru-
bicin and Paclitaxel could not be discriminated by PLS-
DA, further confirming the similarity of the metabolic
response of the two chemotherapeutic agents that were
used in this study.
Discussion
In this study we examined the metabolic effect of NAC
treatment in patients with locally advanced breast can-
cer. By comparing MR spectra of biopsies taken pre-
and post-treatment, significant metabolic changes in
response to treatment were found both by paired and
unpaired multivariate models. The results using paired
multilevel PLS-DA were however superior to those of
unpaired PLS-DA, thus taking advantage of the multile-
vel structure in the data set was clearly beneficial.
Epirubicin and Paclitaxel appear to affect the metabo-
lism of the tumor cells in the same manners, as evi-
denced both by indistinguishable metabolic responses
and similar metabolic traits of the post-treatment spec-
tra. Anthracyclines work by inducing damage to the
Table 3 Changes in relative intensities of metabolites in
response to NAC
Survivors (n = 44) Non-survivors (n =
19)
Metabolite ppm Mean ± SE p-value Mean ± SE p-value
Lactate 4.08-4.13 2.8 ± 15.3 0.815 97.1 ± 26.4 0.004**
Glycine 3.54-3.56 -19.6 ± 8.0 0.047* 0.8 ± 14.3 0.601
GPC 3.22-3.24 -59.6 ± 14.6 < 0.001** -11.8 ± 15.7 0.469
PC 3.21-3.22 -95.4 ± 24.3 < 0.001** -67.4 ± 44.2 0.227
Cho 3.20-3.21 -16.6 ± 6.3 0.013* -17.8 ± 6.3 0.084
tCho 3.20-3.24 -167.2 ± 36.7 < 0.001** -95.3 ± 57.5 0.091
Taurine 3.40-3.43 -0.8 ± 13.2 0.861 6.9 ± 12.5 0.398
b-Glucose 4.61-4.64 17.8 ± 5.1 0.002** -0.2 ± 8.8 0.841
The values (post- minus pre-treatment) of relative intensities are integrated
peak areas from spectra normalized to equal total areas. Wilcoxon sign rank
tests were used for paired statistical analyses. *p < 0.05, ** p < 0.01
Figure 2 PLS-DA of the MR spectra from biopsies excised post-treatment. (A) A score plot separating survivors and non-survivors, (B)
Representative spectra showing the metabolic differences of the tumors of survivors and non-survivors. (C) The loadings of the PLS-DA model
with variables colored according to the VIP scores. b-Glc, b-glucose; Lac, lactate, Gly, glycine; Cr, creatine; Ala, alanine.
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inhibiting cell division [26,27]. However, both treat-
ments will eventually result in cell death. This might
explain why the two agents appear to have similar meta-
bolic responses.
Interestingly, all patients in our study cohort experi-
enced changes in the metabolite profiles in response to
treatment, including also patients categorized to have a
clinically stable disease. No differences in the metabolic
responses of the clinical response groups were detected.
However, when examining the metabolic changes in sur-
vivors and non-survivors independently, a difference in
the metabolic response to NAC was seen. Non-survivors
had a significant increase in lactate levels in response to
treatment, while survivors showed no change in lactate
levels. As a result, a trend of higher levels of lactate was
detected in non-survivors compared to survivors post-
treatment. Increased lactate levels may be a marker for
tumor aggressiveness as high levels of lactate have been
correlated with low survival rates, high incidence of dis-
tant metastasis and recurrence, and increased risk of
radiation resistance in several types of cancer [28-30].
Modification of cell energy metabolism is typically
observed in malignant tumors and is suggested as an
emerging hallmark of cancer [31]. Under normoxic con-
ditions, cancer cells can reprogram their energy metabo-
lism to largely depend on aerobic glycolysis as their
primary energy pathway resulting in increased lactate
production; the so-called Warburg effect. It is not fully
known why cancer cells prefer aerobic glycolysis over
complete oxidation as this would produce far more
ATP. It has been hypothesized that lactate may enhance
the invasiveness of tumor cells and the resulting low pH
may help tumor cells evade tumor-attacking immune
cells [32].
In addition to aerobic glycolysis, breast cancer cells
are often hypoxic due to poor blood supply [33]. It can
be assumed that the large tumors of patients with locally
advanced breast cancer will be affected by hypoxia.
Hypoxia can induce the transcription factor hypoxia
inducible factor-1a (HiF-1a), which in turn upregulates
multiple genes involved in the glycolytic pathway, angio-
genesis, cell proliferation, and other mechanisms
[33-35]. Furthermore HIF-1a promotes transcription of
lactate dehydrogenase (LDH) and lactate monocarboxy-
late transporters (MCT), and thus plays an important
role in the production and efflux of lactate in cancer
cells [36,37]. Inhibition of LDH by small interfering
RNA (siRNA) in mouse breast tumors has been shown
to reduce the glycolytic activity associated with a
decrease in tumor proliferation and tumorigenic poten-
tial [38]. Thus we can suggest that the increased levels
of lactate after NAC treatment observed in non-survi-
vors may reflect enhancement of aerobic glycolytic activ-
ity and/or hypoxic tumor responses that confer higher
tumor malignancy and poor prognosis. In addition, the
glucose levels were increased in response to treatment
in survivors but not in non-survivors. Studies using
18F-
FDG PET have shown decreased glucose uptake in
tumors after treatment with chemotherapy [39,40]. The
increased glucose level observed in survivors after NAC
may therefore be indicative of decreased aerobic glycoly-
sis and tumor hypoxic response favorable of long term
breast cancer survival.
Survivors had a significant decrease in glycine as a
response to treatment, while it remained unchanged in
non-survivors. This was reflected in the post-treatment
spectra, showing significantly lower levels of glycine in
survivors. In a previous study of patients receiving NAC
w i t ht h ea n t h r a c y c l i n ed o x o r u b i c i n ,w ea l s of o u n d
decreased glycine levels after NAC to be associated with
long term breast cancer survival [15]. The biological
role of glycine in tumor malignancy is still unclear. Sev-
eral studies have elucidated the biomarker potential of
glycine in human brain tumors, where it was found to
positively correlate with tumor grade [41,42]. Higher
levels of glycine have also been detected in pre-clinical
studies of the more aggressive basal-like breast cancer
Table 4 Relative intensities of metabolites at pre- and post-treatment
Pre-treatment (mean ± SE) Post-treatment (mean ± SE)
Metabolites ppm Survivors Non-survivors p-value Survivors Non-survivors p-value
Lactate 4.08-4.13 185.8 ± 11.4 164.6 ± 13.8 0.534 196.2 ± 12.7 250.6 ± 26.0 0.089
Glycine 3.54-3.56 115.0 ± 6.4 120.8 ± 11.0 0.542 91.2 ± 4.1 111.4 ± 8.4 0.033*
GPC 3.22-3.24 167.3 ± 12.4 170.1 ± 23.9 0.949 115.6 ± 6.7 153.9 ± 24.1 0.144
PC 3.21-3.22 247.9 ± 17.0 285.4 ± 34.9 0.338 158.0 ± 16.1 205.5 ± 28.1 0.105
Cho 3.20-3.21 95.4 ± 3.9 108.7 ± 8.3 0.225 79.5 ± 3.7 85.9 ± 6.2 0.276
tCho 3.20-3.24 498.3 ± 26.4 551.3 ± 46.8 0.253 344.9 ± 22.3 434.6 ± 44.6 0.075
Taurine 3.40-3.43 242.6 ± 9.6 222.8 ± 12.4 0.393 248.0 ± 8.1 222.3 ± 9.3 0.144
b-Glucose 4.61-4.64 48.4 ± 3.3 49.3 ± 6.0 1.000 63.6 ± 4.3 53.5 ± 6.6 0.172
The values of relative intensities are integrated peak areas from spectra normalized to equal total areas. Wilcoxon rank sum tests were used for statistical
analyses. *p < 0.05, ** p < 0.01
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patients, high glycine levels detected in malignant breast
tumors have been correlated with poor prognosis [44].
Glycine is mainly synthesized from 3-phosphoglycerate,
an intermediate of the glycolysis. In addition, glycine
can be synthesized from Cho through the glycine-
betaine pathway. We can postulate that the decreased
glycine levels after NAC treatment detected in survivors
are caused by altered glycolysis and/or reduced Cho
levels associated with reduced tumor aggressiveness.
A significant decrease of GPC, PC, Cho levels and the
combined tCho level was detected in survivors in
response to treatment, whereas non-survivors experi-
enced only a trend of decrease in Cho and tCho levels.
As a result, lower tCho levels in survivors compared to
non-survivors post-treatment approached significance.
In a previous publication, we showed that GPC and Cho
concentrations significantly decreased in patients with
long-term survival (≥ 5 years), while non-survivors (< 5
years) had no significant changes in choline phospholi-
pid metabolites in response to doxorubicin [15]. Choline
phospholipid metabolites are important biological com-
pounds in cell membrane synthesis and turnover. In
addition, tCho levels have been associated with
increased malignancy and activation of oncogenic signal-
ing in breast cancer cells [45,46]. Higher tCho concen-
trations have been detected in high-grade breast tumors
and tumors with higher pharmacokinetic parameters
measured with dynamic contrast enhanced MR imaging,
indicating a correlation between choline phospholipid
metabolism and tumor malignancy and angiogenesis
[47,48]. As previously mentioned, cancer cells may
undergo adaptive responses to hypoxia by inducing HiF-
1a. Increased tCho levels and choline kinase alpha
(CHKA) expressions have been detected in prostate can-
cer cells and xenografts models under hypoxic com-
pared to normoxic conditions [49]. In the same study,
the authors found hypoxic tumor regions to be co-loca-
lized with regions of high tCho, which possibly occurred
through the up-regulation of CHKA by HiF-1a.C H K A
i sk n o w nt op l a ya ni m p o r t a n tr o l ei nm a l i g n a n tt r a n s -
formation in several types of cancer [50]. Overexpres-
s i o no fC H K Aa n de l e v a t e dP Ca n dt C h ol e v e l so f
breast cancer cells have been associated with increased
invasiveness and drug resistance [51]. Decreased choline
phospholipid metabolism after NAC treatment may be
associated with lower malignancy that potentially can be
used as a predictor of breast cancer survival.
The metabolic responses to NAC treatment appear
to be similar in patients with partial response and
stable disease. None of the patients in this study had a
progressive disease, whereas patients with a complete
response would not have any tumor tissue left for a
post-treatment biopsy. By definition the group with
stable disease can have up to 50% reduction in tumor
volume, and indeed only two patients in this study had
an equal or increased tumor size after NAC. In that
respect, almost all patients had a biological effect of
the treatment although the tumor reduction was small
for patients with a stable disease. It is conceivable that
a cohort including also patients with progressive dis-
ease would reveal clearer differences in metabolic
response between the clinical response groups. It is
however noteworthy that all patients in this study in
general had a decrease in tCho after NAC, as tCho is
suggested as an in vivo biomarker for clinical treat-
ment response. Using current in vivo systems, the dif-
ferent choline-containing compounds can not be
separated by
1H MRS, and metabolites such as lactate
and glycine are not visible using standard in vivo pro-
tocols. Ex vivo studies can therefore provide informa-
tion that is not achievable in current clinical in vivo
systems. However, future technological improvements
of in vivo systems and the implementation of spectral
editing and hyperpolarization techniques can enable
the translation of ex vivo findings into in vivo clinical
use.
In this patient cohort, the prediction of overall survi-
val was accomplished with 70.1% classification accuracy
using post-treatment spectra, but no prognostic infor-
mation could be extracted from the pre-treatment spec-
tra. This shows that the difference between survivors
and non-survivors post-treatment results from a meta-
bolic response to the treatment. The observed higher
levels of lactate and glycine in non-survivors compared
to survivors support our previous studies postulating
high lactate and glycine levels to be predictive of low
breast cancer survival rates (< 5 years).
The tissue samples examined in this study have been
stored in liquid nitrogen since 1997-2003. However, no
significant metabolite degradation due to storage time
h a sb e e nr e p o r t e du s i n gH RM A SM R S[ 5 2 ] .I na d d i -
tion, the tissue samples were prepared on ice and MR
experiments were performed at 4°C which will reduce
the degradation process. The metabolic patterns
observed in this study should therefore not be affected
by sample storage and preparation.
Prediction of survival in patients receiving NAC is
challenging. As NAC will downstage and potentially
completely remove the disease, standard prognostic indi-
cators such as tumor size and lymph node status are no
longer fully applicable after NAC. Several studies have
shown that a pathological complete response after NAC
is associated with better survival rates [4]. However,
approximately 80% of patients will have residual tumor
in the breast after treatment [4]. Our study shows that
the metabolic response to treatment may be an indicator
of patient prognosis.
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By comparing HR MAS MR spectra from biopsies
excised before and after NAC treatment, we have
revealed significant metabolic changes in breast cancer
tumors as a response to treatment. Different metabolic
responses could be related to patient outcome, but did
not separate patients with partial response from those
with stable disease after treatment. Non-survivors had
increased tumor levels of lactate after treatment, while
survivors experienced a decrease in the levels of glycine
and choline-containing compounds. These differences in
tumor response may reflect tumor aggressiveness asso-
ciated with breast cancer survival. Monitoring metabolic
responses to NAC by HR MAS MRS may provide infor-
mation about tumor biology related to prognosis, and
help identify pathways for targeted therapies.
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